Fujifilm Kyowa Kirin Biologics
Biosimilar developer, Japan. 1 development product across 1 molecule: adalimumab.
First approval in the Atlas: Sep 2018, Hulio, adalimumab (EMA)
FDAproducts approved1
EMAproducts approved1
PMDAproducts approved1
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered1
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Adalimumab | Hulio FKB327 | Jul 2020 | Sep 2018 | Jun 2020 | Nov 2020 | ยท | May 2025 |
Month shown is the first approval or registration of that product in that market.
Chronology
- EMASep 2018Hulio, adalimumab
- PMDAJun 2020Adalimumab BS FKB, adalimumab
- FDAJul 2020Hulio, adalimumab
- HCNov 2020Hulio, adalimumab
- EDEMay 2025Hulio, adalimumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.